Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director | June 24, 2026 | June 25, 2026 |
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Director | June 14, 2022 | June 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Foghorn Therapeutics Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23 | Direct | 28,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
Korsana Biosciences, Inc.
Report date June 14, 2022 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.53 · Expires 2032-06-14 | Direct | 20,000 |
Reported balance
After 2022-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-14 · Grant · Acquired 20,000 · Balance 20,000 F1: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 25, 2026 20:03 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 28,000 | $4.08 Strike: $4.08 | $114,240.00 |
DisclosureSEC source: 0001591109-26-000004 · primarydocument.xml · derivative · entry 1 Mendelsohn Michael · CIK 0001591109 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. Read SEC document |
| June 17, 2025 Filed Jun 17, 2025 20:28 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 25,000 | $4.79 Strike: $4.79 | $119,750.00 |
DisclosureSEC source: 0001562180-25-004907 · primarydocument.xml · derivative · entry 1 Mendelsohn Michael · CIK 0001591109 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-16 Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:07 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 16,000 | $5.52 Strike: $5.52 | $88,320.00 |
DisclosureSEC source: 0001562180-24-005362 · primarydocument.xml · derivative · entry 1 Mendelsohn Michael · CIK 0001591109 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-06-25 Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 00:10 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001562180-23-005474 · primarydocument.xml · derivative · entry 1 Mendelsohn Michael · CIK 0001591109 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-20 Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 01:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 16,000 | $0.00 Strike: $13.81 | $0.00 |
DisclosureSEC source: 0001562180-22-005319 · primarydocument.xml · derivative · entry 1 Mendelsohn Michael · CIK 0001591109 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-20 Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 00:56 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001140361-22-023334 · form4.xml · derivative · entry 1 Mendelsohn Michael · CIK 0001591109 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 20:54 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 12,530 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001562180-21-004936 · primarydocument.xml · derivative · entry 1 Mendelsohn Michael · CIK 0001591109 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,530 Underlying: Common Stock · 12,530 shares Expires 2031-07-12 F1 · derivative.exercise_date: The options will vest in full on the first anniversary of the date of grant, subject to the director's continued service on our Board of Directors. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 21:14 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001140361-21-022553 · form4.xml · derivative · entry 1 Mendelsohn Michael · CIK 0001591109 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-24 F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:16 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001209191-20-037568 · doc4.xml · derivative · entry 1 Mendelsohn Michael · CIK 0001591109 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:58 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.95 | $0.00 |
DisclosureSEC source: 0001209191-19-034382 · doc4.xml · derivative · entry 1 Mendelsohn Michael · CIK 0001591109 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-01 F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:23 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 2,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023494 · doc4.xml · nonDerivative · entry 1 Mendelsohn Michael · CIK 0001591109 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,421 F1 · kind: Represents a restricted stock award that vests as to 100% of the shares of Common Stock on May 30, 2019, subject to the director's continuing service to the Company through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.